<DOC>
	<DOCNO>NCT00813384</DOCNO>
	<brief_summary>First human , open-label , sequential dose escalation expansion study AMG 208 subject advance solid tumor .</brief_summary>
	<brief_title>A Phase 1 Study AMG 208 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Men woman ≥ 18 year old Subjects must pathologically document , definitively diagnose , advance solid tumor refractory standard treatment , standard therapy available subject refuse standard therapy Measurable disease per RECIST guideline ( subject nonmeasurable , evaluable disease also eligible Part 1 study ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Life expectancy &gt; 3 month , opinion investigator Female subject postmenopausal ( menstrual period minimum 12 month ) , surgically sterilize . Female subject child bear potential must remain abstinent use doublebarrier birth control method period therapy must willing use contraception 2 week follow last study drug administration negative serum pregnancy test upon entry study Male subject willing use contraception upon enrollment , course study 12 week follow last study drug administration Willing provide tumor sample / slide Competent sign date Institutional Review Board approve inform consent form Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin &gt; 9 g/dL Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.5 x institutional upper limit normal ( IULN ) Renal function , follow : Serum creatinine &lt; 2.0 mg/dL Hepatic function , follow : AST/ALT &lt; 3x ULN total bilirubin &lt; 1.5x ULN subject Alkaline phosphatase &lt; 2.0 x ULN ( liver bone metastasis present , ≤ 5 x ULN ) Any disorder compromise ability subject give write informed consent and/or comply study procedure . Primary central nervous system ( CNS ) tumor metastases History bleed diathesis Myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication , uncontrolled hypertension opinion investigator A baseline ECG QTc &gt; 480 m Active infection within 2 week study enrollment ( day 1 ) Significant gastrointestinal disorder ( ) , opinion investigator , ( e.g . Crohn 's disease , ulcerative colitis , extensive gastrointestinal resection ) may influence drug absorption Known positive test HIV Known acute chronic hepatitis B hepatitis C infection , determine serologic test Unresolved toxicity prior antitumor therapy , define resolve CTCAE grade 0 1 , level dictate eligibility criterion exception alopecia Antitumor therapy ( chemotherapy , antibody therapy , molecular target therapy , retinoid therapy , hormonal therapy , investigational agent ) within 28 day study day 1 ( six week nitrosureas , mitomycin C , antibody molecular target agent t1/2 &gt; 10 day ) ; concurrent use hormone deprivation therapy hormonerefractory prostate cancer breast cancer permit Treatment immune modulators include , limited , systemic corticosteroid , cyclosporine tacrolimus within two week prior enrollment Therapeutic palliative radiation therapy within 2 week study day 1 Concurrent prior ( within 7 day study day 1 ) anticoagulation therapy ( lowdose warfarin [ ≤ 2 mg/day ] low molecular weight heparin prophylaxis central venous catheter thrombosis aspirin [ 81 mg/day ] allow ) Prior participation investigational study and/or procedure within 28 day study day 1 Major surgery within 30 day study day 1 Any comorbid medical disorder may increase risk toxicity , opinion investigator sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Phase 1</keyword>
	<keyword>C-met inhibitor</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>